CN104334744A - 预测、诊断和治疗特发性肺纤维化的方法 - Google Patents

预测、诊断和治疗特发性肺纤维化的方法 Download PDF

Info

Publication number
CN104334744A
CN104334744A CN201380027564.8A CN201380027564A CN104334744A CN 104334744 A CN104334744 A CN 104334744A CN 201380027564 A CN201380027564 A CN 201380027564A CN 104334744 A CN104334744 A CN 104334744A
Authority
CN
China
Prior art keywords
seq
ipf
antibody
genes
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380027564.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·R·阿巴斯
J·R·阿罗恩
S·钱德里阿尼
G·贾
N·J·I·卢因-科赫
D·德皮安托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN201611178102.8A priority Critical patent/CN107099581B/zh
Publication of CN104334744A publication Critical patent/CN104334744A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201380027564.8A 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法 Pending CN104334744A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611178102.8A CN107099581B (zh) 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261616394P 2012-03-27 2012-03-27
US61/616,394 2012-03-27
US201261707411P 2012-09-28 2012-09-28
US61/707,411 2012-09-28
PCT/US2013/031178 WO2013148232A1 (en) 2012-03-27 2013-03-14 Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611178102.8A Division CN107099581B (zh) 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法

Publications (1)

Publication Number Publication Date
CN104334744A true CN104334744A (zh) 2015-02-04

Family

ID=49261043

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380027564.8A Pending CN104334744A (zh) 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法
CN201611178102.8A Active CN107099581B (zh) 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611178102.8A Active CN107099581B (zh) 2012-03-27 2013-03-14 预测、诊断和治疗特发性肺纤维化的方法

Country Status (16)

Country Link
US (2) US20160230226A1 (cg-RX-API-DMAC7.html)
EP (2) EP3725892A1 (cg-RX-API-DMAC7.html)
JP (1) JP6404208B2 (cg-RX-API-DMAC7.html)
KR (1) KR102197524B1 (cg-RX-API-DMAC7.html)
CN (2) CN104334744A (cg-RX-API-DMAC7.html)
AR (1) AR090339A1 (cg-RX-API-DMAC7.html)
AU (2) AU2013240344A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014023348A2 (cg-RX-API-DMAC7.html)
CA (1) CA2864884A1 (cg-RX-API-DMAC7.html)
HK (1) HK1206796A1 (cg-RX-API-DMAC7.html)
IL (1) IL256396A (cg-RX-API-DMAC7.html)
MX (2) MX370486B (cg-RX-API-DMAC7.html)
NZ (1) NZ628458A (cg-RX-API-DMAC7.html)
RU (1) RU2014139546A (cg-RX-API-DMAC7.html)
SG (2) SG11201405830VA (cg-RX-API-DMAC7.html)
WO (1) WO2013148232A1 (cg-RX-API-DMAC7.html)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104792998A (zh) * 2015-03-09 2015-07-22 中国人民解放军第四军医大学 Loxl2抗原用于制备甲状腺癌预示、侵袭、转移试剂盒的应用
CN105400870A (zh) * 2015-11-11 2016-03-16 南方医科大学 CD1c在菌阴肺结核诊断中的应用
WO2016206596A1 (zh) * 2015-06-26 2016-12-29 上海市肿瘤研究所 Cthrc1在肝硬化诊断和治疗中的应用
CN106319058A (zh) * 2016-08-31 2017-01-11 汪道文 一种检测特发性肺纤维化致病基因的dna文库及其应用
CN108931645A (zh) * 2018-07-26 2018-12-04 北京大学第医院 一种hcv清除后肝纤维化评估系统及评估方法
CN109689892A (zh) * 2016-09-07 2019-04-26 威拉赛特公司 用于检测寻常型间质性肺炎的方法和系统
CN115925920A (zh) * 2022-08-04 2023-04-07 北京顺元天生物制品有限公司 一种基因增强型免疫细胞治疗肝硬化的方法
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12110554B2 (en) 2009-05-07 2024-10-08 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
CN119162300A (zh) * 2024-09-12 2024-12-20 中国人民解放军陆军军医大学第一附属医院 用于预测肺纤维化程度及预后情况的标志物、模型及应用
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US12305238B2 (en) 2008-11-17 2025-05-20 Veracyte, Inc. Methods for treatment of thyroid cancer
WO2026026420A1 (zh) * 2024-07-30 2026-02-05 上海交通大学医学院附属仁济医院 一种慢性肝纤维化性疾病的诊断系统

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013035799A1 (ja) 2011-09-06 2013-03-14 株式会社シノテスト ペリオスチンの特定領域に結合する抗体及びこれを用いたペリオスチンの測定方法
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
JP6715767B2 (ja) * 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
JP6312054B2 (ja) * 2013-11-06 2018-04-18 学校法人日本大学 間質性肺炎のバイオマーカー
EP3068409A4 (en) * 2013-11-14 2017-08-23 Proterris, Inc. Treatment or prevention of pulmonary conditions with carbon monoxide
WO2015138034A2 (en) * 2013-12-20 2015-09-17 President And Fellows Of Harvard College Low shear microfluidic devices and methods of use and manufacturing thereof
US9970935B2 (en) 2014-02-06 2018-05-15 The Brigham And Women's Hospital, Inc. Uses of GLI1 in detecting tissue fibrosis
TW201618795A (zh) 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
WO2015164716A1 (en) * 2014-04-25 2015-10-29 Brown University Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with hermansky pudlak syndrome
US9913819B2 (en) 2014-06-12 2018-03-13 Yale University Methods of treating or preventing fibrotic lung diseases
EP2957634A1 (en) 2014-06-20 2015-12-23 Consejo Superior De Investigaciones Científicas Compounds for prevention and/or treatment of fibrotic diseases
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
HRP20240306T1 (hr) 2015-10-27 2024-05-10 Taipei Medical University Derivati indolina za liječenje i/ili prevenciju fibroznih bolesti
HK1254295A1 (zh) 2015-11-23 2019-07-19 默克专利股份有限公司 用於治疗纤维化和/或纤维化病症的抗-αＶ整合素抗体
MX2018006269A (es) * 2015-11-23 2018-09-05 Merck Patent Gmbh Anticuerpo anti-alfa-v-integrina para el tratamiento de fibrosis y/o trastornos fibroticos.
JP2019522638A (ja) * 2016-05-27 2019-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブ及びピルフェニドンによる治療開始を判定するためのｅｃｍバイオマーカーの使用
US11397178B2 (en) 2016-10-28 2022-07-26 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy
US20200017913A1 (en) * 2017-03-02 2020-01-16 President And Fellows Of Harvard College Methods and systems for predicting treatment responses in subjects
IT201700026858A1 (it) * 2017-03-10 2018-09-10 Univ Degli Studi Padova Uso di inibitori delle serin proteasi, in particolare di serpinb3
US20190127456A1 (en) * 2017-10-31 2019-05-02 Fibrogen, Inc. Methods of treating idiopathic pulmonary fibrosis
KR102958241B1 (ko) 2018-09-10 2026-04-30 레인 테라퓨틱스, 인크. Cav-1 단백질의 변형된 펩타이드 단편 및 섬유증의 치료에 있어서 이의 용도
CN112969921B (zh) * 2018-10-29 2024-06-07 国立大学法人东京医科齿科大学 取得间质性肺炎患者的呼吸功能的降低风险相关信息的方法及其利用
US12480960B2 (en) 2019-01-11 2025-11-25 University Of Virginia Patent Foundation Compositions and methods for predicting lung function decline in idiopathic pulmonary fibrosis
WO2022026922A2 (en) * 2020-07-31 2022-02-03 Genentech, Inc. Methods for treating exacerbations of inflammatory respiratory diseases
EP4297768A4 (en) 2021-02-25 2025-01-15 Lung Therapeutics, LLC Biomarkers for the treatment of interstitial lung disease
JP2024523034A (ja) * 2021-06-18 2024-06-25 エフ． ホフマン－ラ ロシュ アーゲー 二重特異性抗ｃｃｌ２抗体
ES2957479B2 (es) * 2022-06-07 2025-07-28 Baigene S L Metodo de obtencion de datos utiles para la prediccion del riesgo de un sujeto de sufrir fibrosis
KR20250025381A (ko) 2022-06-17 2025-02-21 아포지 바이오로직스, 인크. 인터류킨 13에 결합하는 항체 및 사용 방법
US20260008845A1 (en) * 2022-11-14 2026-01-08 Alentis Therapeutics Ag Biomarkers for fibrosis treatment using anti-claudin-1 antibodies
CN117747093B (zh) * 2024-02-20 2024-06-07 神州医疗科技股份有限公司 一种特发性肺纤维化诊断模型的构建方法及诊断系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101375157A (zh) * 2006-01-13 2009-02-25 印第安纳大学研究和科技公司 用于治疗涉及对肺中存在的结缔组织自身免疫反应的肺病的分子
CN105169390A (zh) * 2010-12-16 2015-12-23 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
MX361174B (es) * 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US20080044420A1 (en) 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
KR101363777B1 (ko) 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―１３ 항체 조성물
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
BRPI0718225A2 (pt) * 2006-10-05 2013-11-12 Centocor Ortho Biotech Inc Antagonistas de ccr2 para tratamento de fibrose
WO2008083695A1 (de) 2006-12-20 2008-07-17 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Vorrichtung und verfahren zur messung der intensität des lichtes einer ersten gruppe von lichtquellen einer beleuchtungseinheit
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2705486C (en) * 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
NZ601815A (en) * 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
WO2010028274A1 (en) * 2008-09-05 2010-03-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
CA2744588A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Ligands that bind il-13
US8911960B2 (en) * 2009-06-01 2014-12-16 Case Western Reserve University Method for identifying idiopathic pneumonia progression by measuring the level of mannose-binding protein C

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101375157A (zh) * 2006-01-13 2009-02-25 印第安纳大学研究和科技公司 用于治疗涉及对肺中存在的结缔组织自身免疫反应的肺病的分子
CN105169390A (zh) * 2010-12-16 2015-12-23 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12305238B2 (en) 2008-11-17 2025-05-20 Veracyte, Inc. Methods for treatment of thyroid cancer
US12297503B2 (en) 2009-05-07 2025-05-13 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US12110554B2 (en) 2009-05-07 2024-10-08 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing
US12534763B2 (en) 2014-11-05 2026-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis
CN104792998A (zh) * 2015-03-09 2015-07-22 中国人民解放军第四军医大学 Loxl2抗原用于制备甲状腺癌预示、侵袭、转移试剂盒的应用
WO2016206596A1 (zh) * 2015-06-26 2016-12-29 上海市肿瘤研究所 Cthrc1在肝硬化诊断和治疗中的应用
CN106290892A (zh) * 2015-06-26 2017-01-04 上海市肿瘤研究所 Cthrc1在肝硬化诊断和治疗中的应用
CN111718413A (zh) * 2015-06-26 2020-09-29 上海市肿瘤研究所 Cthrc1在肝硬化诊断和治疗中的应用
CN105400870B (zh) * 2015-11-11 2018-09-25 南方医科大学 CD1c在菌阴肺结核诊断中的应用
CN105400870A (zh) * 2015-11-11 2016-03-16 南方医科大学 CD1c在菌阴肺结核诊断中的应用
CN106319058B (zh) * 2016-08-31 2019-09-10 汪道文 一种检测特发性肺纤维化致病基因的dna文库及其应用
CN106319058A (zh) * 2016-08-31 2017-01-11 汪道文 一种检测特发性肺纤维化致病基因的dna文库及其应用
CN109689892A (zh) * 2016-09-07 2019-04-26 威拉赛特公司 用于检测寻常型间质性肺炎的方法和系统
CN108931645A (zh) * 2018-07-26 2018-12-04 北京大学第医院 一种hcv清除后肝纤维化评估系统及评估方法
CN115925920A (zh) * 2022-08-04 2023-04-07 北京顺元天生物制品有限公司 一种基因增强型免疫细胞治疗肝硬化的方法
WO2026026420A1 (zh) * 2024-07-30 2026-02-05 上海交通大学医学院附属仁济医院 一种慢性肝纤维化性疾病的诊断系统
CN119162300A (zh) * 2024-09-12 2024-12-20 中国人民解放军陆军军医大学第一附属医院 用于预测肺纤维化程度及预后情况的标志物、模型及应用

Also Published As

Publication number Publication date
SG10201702842SA (en) 2017-06-29
CA2864884A1 (en) 2013-10-03
AU2013240344A1 (en) 2014-09-18
CN107099581B (zh) 2021-07-13
WO2013148232A1 (en) 2013-10-03
AR090339A1 (es) 2014-11-05
US20190062836A1 (en) 2019-02-28
KR102197524B1 (ko) 2020-12-31
US20160230226A1 (en) 2016-08-11
EP3725892A1 (en) 2020-10-21
HK1206796A1 (en) 2016-01-15
BR112014023348A2 (pt) 2019-03-19
JP6404208B2 (ja) 2018-10-10
KR20140143196A (ko) 2014-12-15
EP2831280A4 (en) 2016-02-24
CN107099581A (zh) 2017-08-29
AU2018250393A1 (en) 2018-11-08
MX2014011503A (es) 2014-12-05
IL256396A (en) 2018-02-28
RU2014139546A (ru) 2016-05-20
JP2015522246A (ja) 2015-08-06
EP2831280B1 (en) 2020-04-15
NZ628458A (en) 2016-11-25
MX370486B (es) 2019-12-16
MX2019015159A (es) 2020-02-19
SG11201405830VA (en) 2014-10-30
EP2831280A1 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
JP6404208B2 (ja) 特発性肺線維症の予後予測、診断および処置の方法
Kamiya et al. Immune mechanisms in fibrotic interstitial lung disease
KR102070761B1 (ko) 천식을 치료 및 진단하기 위한 조성물 및 방법
US10538813B2 (en) Biomarker panel for diagnosis and prediction of graft rejection
JP5650871B1 (ja) そう痒を伴う疾患に罹患した患者のｉｌ−３１アンタゴニストによる治療に対する応答を予測する方法
EP3974450A2 (en) Biomarker
JP2012533322A (ja) クローン病のための遺伝子発現マーカー
EP2831104A1 (en) Biomarkers for use in integrin therapy applications
KR20180036788A (ko) 원형 탈모증 치료를 위한 바이오마커
CN101970689A (zh) 炎性肠病的基因表达标志物
CN116997663A (zh) 类风湿性关节炎发作的标志物和细胞前因
JP7685461B2 (ja) 多発性硬化症の遺伝子発現マーカー及び治療
JP2020531439A (ja) アトピー性皮膚炎の治療及び治療選択のための組成物及び方法
KR101801092B1 (ko) 특발성 페섬유증 진단용 마커 조성물 및 특발성 폐섬유증 진단을 위한 정보제공방법
JP6531306B2 (ja) 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
CN110499365B (zh) Agap9在制备诊断骨关节炎的产品中的应用
HK1242740B (en) Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
HK1242740A1 (en) Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
EP3133400B1 (en) Use of ak6 and gpx5 male fertility related proteins or combination thereof
Vuljan Idiopathic Pulmonary Fibrosis (IPF): tissue identification of crucial biomarkers by RNA-Sequencing approach.
JP2006174740A (ja) アレルギー性疾患の疾患マーカーおよびその利用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206796

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150204

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1206796

Country of ref document: HK